普瑞巴林治疗肢体神经病理性疼痛的近期疗效和安全性观察

目的评价普瑞巴林用于治疗神经刺激引起肢体神经病理性疼痛的临床近期疗效及其安全性。方法回顾性分析2011年2月至2011年12月在我院住院的78例明确诊断肢体神经病理性疼痛患者的资料。本组患者均在手术前使用普瑞巴林口服进行镇痛治疗。观察口服普瑞巴林48h后患者的镇痛效果和不良反应，疼痛程度评估分别使用VAS评分（0为无痛，10为疼痛不能忍受）和LANSS评分（即利兹评分，0为无痛，16分为剧烈疼痛）。结果用药后大部分患者疼痛均有不同程度的改善，改善率为81％（63／78）。用药后48h患者的平均VAS评分从用药前的6．8±2．4降到了用药后的3．8±3．2；平均LANSS评分从用药前的11．1±3．4降到了用药后的6．3±4．7，用药前后2组评分均有统计学差异（P〈0．051。本组病例所有患者治疗期间均未出现严重的不良反应。结论普瑞巴林治疗神经源性肢体病理性疼痛疗效明确，不良反应较轻，发生率较低。

The short-term efficacy and safety observation of pregabalin in the treatment of limb neuropathic pain

Objective To evaluate the short-term clinical efficacy and safety of pregabalin in the treatment of limb neuropathic pain caused by neural stimulation. Methods 78 patients definitely diagnosed as limb neuropathic pain was adopted by our hospital from February 2011 to December 2011, whose data were retrospectively analyzed. They all received oral pregabalin preoperatively. The analgesic effects and side effects were observed in 48 hours after oral pregabalin administration. The severity of pain was assessed using a visual analogue scale （VAS） （no pain 0, severe pain 10） and the Leeds assessment of neuropathic symptoms and signs （LANSS） scale （no pain 0, severe pain 16）. Results Most of the patients received pain relief to some extent after medication, and the improvement rate was 81% （63/78）. The mean VAS score reduced from 6.8±2.4 to 3.8±3.2, while the mean LANSS score reduced from 11.1±3.4 to 6.3±4.7 in 48 hours after medication. There were statistical differences in both VAS and LANSS scores between pre- and post- medication （P〈0.05）. No severe side effect was found in patients in our group during the treating therapy. Conclusions Pregabalin is effective in treating limb neuropathic pain, with minor side effects and lower incidence.